Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STop and restart Acalabrutinib In fRail patients with previously untreated CLL (STAIR-ACALA)
2020-006081-36Phase 2Active
- Sponsor
- Filo
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Filo. Primary endpoint: Progression-free survival at one year post-acalabrutinib discontinuation. Started Jun 2021; status: active.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2020-006081-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006081-36.